Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,221 to 1,240 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| BMD Result Letter and Brochure vs Control: deaths from any cause | 26 of 3,898 18 of 3,851 | 0.2 points -0.1 to 0.6 | 7,749 | NCT01507662 Patient Activation After DXA Result Notification |
| MenACWY-CRM197 + Routine Vaccines (All) vs Routine Vaccines (All): serious adverse events | 354 of 5,760 114 of 1,968 | 0.4 points -0.9 to 1.5 | 7,728 | NCT00806195 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants |
| No-intervention Control vs Social Influences School-based Smoking Prevention Curriculum: Number of Participants Smoking Daily at 12th Grade | 995 of 3,876 976 of 3,847 | 0.3 points -1.6 to 2.2 | 7,723 | NCT00115869 Hutchinson Smoking Prevention Project |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality, MI or IDR | 343 of 3,860 327 of 3,827 | 0.3 points -0.9 to 1.6 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of Stroke | 5 of 3,860 7 of 3,827 | -0.1 points -0.3 to 0.1 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality | 34 of 3,860 29 of 3,827 | 0.1 points -0.3 to 0.5 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of IDR | 44 of 3,860 52 of 3,827 | -0.2 points -0.7 to 0.3 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality or MI | 321 of 3,860 298 of 3,827 | 0.5 points -0.7 to 1.7 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of MI | 297 of 3,860 276 of 3,827 | 0.5 points -0.7 to 1.7 | 7,687 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| With Previous Treatment vs Without Previous Treatment: Risk Factors for the Proportion of Responders of Tolterodine-Previous Treatment | 698 of 943 5,753 of 6,736 | -11.4 points -14.4 to -8.6 | 7,679 | NCT01488578 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All Cause Mortality | 116 of 3,851 120 of 3,818 | -0.1 points -0.9 to 0.6 | 7,669 | NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor |
| Cervarix/Engerix-B A Group vs Cervarix/Engerix-B B Group: Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With HPV-16/18 Types in Cervarix/Engerix-B A Group Versus Cervarix/Engerix-B B Group | 139 of 3,629 117 of 4,029 | 0.9 points 0.1 to 1.8 | 7,658 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Insulin Degludec vs Insulin Glargine: Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no) | 187 of 3,818 252 of 3,819 | -1.7 points -2.8 to -0.7 | 7,637 | NCT01959529 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events |
| Insulin Degludec vs Insulin Glargine: serious adverse events | 1,473 of 3,818 1,517 of 3,819 | -1.1 points -3.3 to 1.0 | 7,637 | NCT01959529 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events |
| Comfort Talk® Training vs Control: No-shows in Q4FY15 = Baseline Quarter (OSU) | 218 of 4,158 216 of 3,446 | -1.0 points -2.1 to 0.0 | 7,604 | NCT02427737 Comfort Talk and Economic Outcomes in MRI |
| Exemestane vs Anastrozole: Clinical Fracture Rate: Number of Participants With Bone Fractures. | 358 of 3,789 354 of 3,787 | 0.1 points -1.2 to 1.4 | 7,576 | NCT00066573 Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer |
| Exemestane vs Anastrozole: Distant Disease-free Survival: Number of Participants Without Documented Distant Recurrence | 157 of 3,789 164 of 3,787 | -0.2 points -1.1 to 0.7 | 7,576 | NCT00066573 Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer |
| With Urinary Urgency vs Without Urinary Urgency: Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency | 5,529 of 6,521 829 of 1,043 | 5.3 points 2.8 to 8.0 | 7,564 | NCT01488578 Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) |
| Clopidogrel + ASA vs Placebo + ASA: Adjudicated Major Bleedings | 251 of 3,772 162 of 3,782 | 2.4 points 1.3 to 3.4 | 7,554 | NCT00249873 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A) |
| Clopidogrel + ASA vs Placebo + ASA: Death From Any Cause (Cardiovascular and Noncardiovascular) | 825 of 3,772 841 of 3,782 | -0.4 points -2.2 to 1.5 | 7,554 | NCT00249873 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=62
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01507662-deaths",
"title": "BMD Result Letter and Brochure vs Control: deaths from any cause",
"summary": "26 of 3898 against 18 of 3851; risk difference 0.2 points, 95% interval -0.1 to 0.6; NCT01507662, Patient Activation After DXA Result Notification",
"record": "/library/comparisons/NCT01507662-deaths",
"nct_id": "NCT01507662",
"kind": "deaths",
"participants": 7749,
"risk_difference": {
"value": 0.0019959766035995263,
"lower": -0.0014352939492274092,
"upper": 0.005526263050830323
},
"group_1": "26 of 3,898",
"group_2": "18 of 3,851",
"difference": "0.2 points",
"interval": "-0.1 to 0.6",
"trial_title": "Patient Activation After DXA Result Notification"
},
{
"id": "NCT00806195-sae",
"title": "MenACWY-CRM197 + Routine Vaccines (All) vs Routine Vaccines (All): serious adverse events",
"summary": "354 of 5760 against 114 of 1968; risk difference 0.4 points, 95% interval -0.9 to 1.5; NCT00806195, Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",
"record": "/library/comparisons/NCT00806195-sae",
"nct_id": "NCT00806195",
"kind": "serious-adverse-events",
"participants": 7728,
"risk_difference": {
"value": 0.0035315040650406443,
"lower": -0.009141473159875709,
"upper": 0.015030091227981372
},
"group_1": "354 of 5,760",
"group_2": "114 of 1,968",
"difference": "0.4 points",
"interval": "-0.9 to 1.5",
"trial_title": "Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=63",
"request_id": "FzoPdvJSOu3MUt7k"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant